/home/corante/public_html/pipeline/ en-us derek-lowe@sbcglobal.net 2008-08-20T07:29:47-05:00 hourly 1 2000-01-01T12:00+00:00 http://pipeline.corante.com/archives/2008/08/20/replacing_whats_being_lost.php Well, today’s subject isn’t a cheerful data set, but it certainly deserves some thought. Over at Pharmalot, Ed Silverman has some data from consulting firm AVOS Life Sciences, who have sat down to estimate how well various drug companies will... 73503@/home/corante/public_html/pipeline/ Drug Development 2008-08-20T07:29:47-05:00 http://pipeline.corante.com/archives/2008/07/24/confident.php I’m going to expand on one of the points brought up yesterday, about the reported drug industry executive who was confident that his company’s Alzheimer’s therapy was ready to go out and make billions of dollars. It was that word... 73463@/home/corante/public_html/pipeline/ Drug Development 2008-07-24T07:16:22-05:00 http://pipeline.corante.com/archives/2008/07/07/pfizers_prospects_just_ducky.php I thought I’d start out the week by opening the mailbag for a recent reply to my posts about Pfizer’s research cutbacks. Here’s a perspective that you won’t get from me, at any rate: You never surprise me of your... 73423@/home/corante/public_html/pipeline/ Business and Markets 2008-07-07T07:17:28-05:00 http://pipeline.corante.com/archives/2008/06/02/a_breath_of_fresh_air_from_fuji.php A longtime reader pointed me to this article from Business Week. Fuji Film of Japan, facing all kinds of problems like the other film makers of the world, has decided to put some of its money into a more exciting,... 73344@/home/corante/public_html/pipeline/ Business and Markets 2008-06-02T07:22:48-05:00 http://pipeline.corante.com/archives/2008/05/28/awash_in_yen.php So Takeda has opened up its roomy wallet once again, and signed on with Alnylam for a nonexclusive partnership in oncology and metabolics. The InVivoBlog has all the details, but the main point is that Takeda had to put $100... 73335@/home/corante/public_html/pipeline/ Business and Markets 2008-05-28T07:23:43-05:00 http://pipeline.corante.com/archives/2008/05/21/lurching_around_for_fun_and_profit.php I’ve been in this business for almost 19 years now. That means that the drugs that were discovered during my first few years of work are now either on the market or expected to be there soon. Fine, I spent... 73323@/home/corante/public_html/pipeline/ Drug Industry History 2008-05-21T07:13:24-05:00 http://pipeline.corante.com/archives/2008/05/08/merck_bails_on_natural_products.php Every few years, you hear talk of a renaissance in natural products-based drug discovery. Well, this news should postpone the next round of optimism for a bit longer: Merck is cutting their natural products program entirely. They've had a long... 73286@/home/corante/public_html/pipeline/ Drug Industry History 2008-05-08T07:50:51-05:00 http://pipeline.corante.com/archives/2008/05/01/o_pioneers.php Drug Discovery Today has the first part of an article on the history of the molecular modeling field, this one covering about 1960 to 1990. It’s a for-the-record document, since as time goes on it’ll be increasingly hard to unscramble... 73268@/home/corante/public_html/pipeline/ In Silico 2008-05-01T07:26:00-05:00 http://pipeline.corante.com/archives/2008/04/25/why_buy_anyway.php I don’t want to say that this is a trend, but I notice that GSK is saying that they’re going to leave Sirtris more or less alone as well (as Takeda has said they’ll do with Millennium). The researchers in... 73254@/home/corante/public_html/pipeline/ Business and Markets 2008-04-25T07:47:23-05:00 http://pipeline.corante.com/archives/2008/03/24/thats_never_gonna_work.php A colleague and I were talking the other day about the (long) list of drugs that have been left for dead at some point during their development. There are some famous cases – Lipitor, for example, which wasn’t thought by... 73179@/home/corante/public_html/pipeline/ Drug Development 2008-03-24T08:14:21-05:00 http://pipeline.corante.com/archives/2008/03/14/pen_and_paper.php Registering some new compounds for testing, as I’ve been doing recently, has me thinking about how that was done when I started at my first company. This was in the fall of 1989, so while it’s not exactly the Ancient... 73159@/home/corante/public_html/pipeline/ Drug Industry History 2008-03-14T07:27:24-05:00 http://pipeline.corante.com/archives/2008/03/10/hits_misses_and_some_more_misses.php There’s an article in the latest Nature Reviews Drug Discovery on recent drug attrition rates that caught my eye. The authors are looking over 2006-2007 trials and approvals, comparing the biotech industry with traditional pharma. ("Biotech" is defined as a... 73149@/home/corante/public_html/pipeline/ Business and Markets 2008-03-10T07:28:30-05:00 http://pipeline.corante.com/archives/2008/03/05/smaller_wetter_harder_to_work_with.php There’s an interesting article coming out in J. Med. Chem. on antibiotic compounds, which highlights something that’s pretty clear if you spend some time looking at the drugs in that area. We make a big deal (or have made one... 73140@/home/corante/public_html/pipeline/ Infectious Diseases 2008-03-05T08:14:24-05:00 http://pipeline.corante.com/archives/2008/02/20/what_you_become_known_for.php A recent item from InVivoBlog about Merck which brought up some interesting points. They aren’t cheerful ones. The article is largely about Merck’s reputation, which has taken some dents in recent years, to put it lightly. The Vioxx debacle is... 73120@/home/corante/public_html/pipeline/ Drug Industry History 2008-02-20T08:14:48-05:00 http://pipeline.corante.com/archives/2008/01/16/judah_folkman.php So Judah Folkman is no longer with us. He's considered to be the father of the idea that many tumors help to make their own blood supply, through angiogenesis, and that this could be a way to impede their growth.... 73027@/home/corante/public_html/pipeline/ Cancer 2008-01-16T08:20:07-05:00